期刊文献+

奥美拉唑在幽门螺杆菌阳性的十二指肠球部溃疡治疗效果分析 被引量:7

The Effect Analysis of Omeprazole in Helicobacter Pylori-positive Duodenal Ulcer Treatment
暂未订购
导出
摘要 目的观察奥美拉唑在幽门螺杆菌阳性的十二指肠球部溃疡治疗效果。方法 40例幽门螺杆菌阳性的十二指肠球部溃疡患者平分为两组,治疗组给予基于奥美拉唑的三联治疗方法,对照组给予基于埃索美拉唑的三联治疗方法。结果经过治疗后,治疗组总有效率为95.0%,对照组总有效率为75.0%,治疗组临床疗效明显好于对照组(P<0.05)。两组的Hp根除率分别为90.0%和75.0%,统计分析表明治疗组的根除率明显好于对照组(P<0.05)。两组不良反应情况对比无显著性差异(P>0.05)。结论奥美拉唑在幽门螺杆菌阳性的十二指肠球部溃疡治疗效果好,Hp根除多,安全性好,值得推广应用。 Objective To observe the effect of omeprazole in helicobacter pylori-positive duodenal ulcer treatment.Methods 40 patients with helicobacter pylori-positive duodenal ulcer were equally divided into two groups,the treatment group received omeprazole-based triple therapy,the control group received esomeprazole-based triple therapy.Results After the treatment,the total effective rate was 95.0% in the treatment group,the total effective rate was 75.0% in the control group,the clinical efficacy of the treatment group was significantly better than the control group(P〈0.05).Hp eradication rate was 90.0% and 75.0% in the treatment group and the control group,the statistical analysis showed that the eradication rate in the treatment group was significantly better than the control group(P〈0.05).There was no significant difference in adverse reactions of two groups(P〈0.05).Conclusion Omeprazole in helicobacter pylori-positive duodenal ulcer treatment has good effect,more safet in Hp eradication rate,which is worthy of wide application.
出处 《临床医学工程》 2011年第5期689-690,共2页 Clinical Medicine & Engineering
关键词 奥美拉唑 十二指肠球部溃疡 幽门螺旋杆菌 埃索美拉唑 Omeprazole Duodenal ulcer Helicobacter pylori Esomeprazole
  • 相关文献

参考文献6

二级参考文献12

共引文献34

同被引文献61

  • 1胡祥鹏,胡咏梅,许建明,梅俏,徐新华,徐叔云.细胞色素P450 2C19基因多态性对奥美拉唑胶囊抑酸效果的影响[J].中国临床药理学杂志,2006,22(1):31-34. 被引量:7
  • 2梁小燕,高青.质子泵抑制剂的研发进展[J].医学综述,2007,13(4):245-247. 被引量:22
  • 3王珺.雷尼替丁与奥美拉唑三联疗法根除幽门螺旋杆菌的随机对照研究[J].中国基层医药,2007,14(9):1554-1554. 被引量:3
  • 4Ogilvie B W, Yerino P, Kazmi F, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a me- tabolism -dependent inhibitor of CYP2C 19: implications for coadministration with clopidogrel[J]. Drug metabolism and dis- position, 2011, 39(11): 2020-2033.
  • 5Nakagawa S, Arai Y, Kishida T, et al. Lan soprazole inhibits nitric oxide and pros taglandin E2 production in murine ma- crophage RAW 264.7 cells[J]. Inflamma-tion, 2012, 35(3): 1062-1068.
  • 6Reddy MY, Ramesh V, Reddy CK, et al.Validated chromatographic method for the determination of process related genotoxic impurity in lansoprazole[J]. Asian Journal ofResearchin ChemisWy, 2011,4(6): 965-967.
  • 7中华医学杂志编辑委员会.应急性溃疡防治建议[J].中华医学杂志,2002,82(14):l000.
  • 8Holbrook J T,Wise R A,Gold B D,et al.Lansoprazole for children with poorly controlled asthma:a randomized con- trolled trial[J].JAMA:The Journal of the American Medi- cal Association,2012,307(4):373-381.
  • 9Kinoshita Y,Miwa H,Sanada K,et al.Clinical characteris- tics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia[J],Jour- nal of gastroenterology,2014,49(4):628-637.
  • 10Ogilvie B WfYerino P,Kazmi F,et al.The proton pump in- hibitor,omeprazole,but not lansoprazole or pantoprazole,is a metabolism - dependent inhibitor of CYP2C19:implica- tions for coadministration with clopidogrel[J],Drug metab- olism and disposition,2011,39(11):2020-2033.

引证文献7

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部